PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch
Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. ("PharmaTher") to evaluate the delivery of N,N-Dimethyltryptamine (DMT) using PharmaTher's novel...
2023-02-22 8:00 AM EST
PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer
Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company intends to pursue a first-in-human study of its lead development candidate, PD-001, enteric coated cepharanthine-2HCL (for oral administration), in Australia during the...
2023-02-13 7:30 AM EST
PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer
Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has completed filing a PCT (Patent Cooperation Treaty) application for its lead drug, cepharanthine-2HCL (PD-001) for the treatment of prostate cancer, alone or in...
2023-01-31 7:30 AM EST
PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing
Toronto, Ontario--(Newsfile Corp. - October 4, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the C
2022-10-04 7:00 AM EDT
PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022 PharmaDrug extends contract with investigators at Johns Hopkins University in support of forthcoming (Q4, 2022) FDA IND Application for a Phase 1 clinical study to investigate persistent effects of DMT PharmaDrug extends contract with investigator at University of Michigan in anticipation of forthcoming...
2022-08-25 8:00 AM EDT
PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease
Toronto, Ontario--(Newsfile Corp. - August 19, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research
2022-08-19 8:00 AM EDT
Pharmadrug Announces Closing of Sale of German Cannabis Assets
Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("Pharmadrug" or the "Company"), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding securities of Pharmadrug Production GmbH ("Pharmadrug GmbH") to Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron"). Pharmadrug GmbH, is a German medical cannabis distributor, with a Schedule I European Union narcotics...
2022-08-03 8:06 AM EDT
PharmaDrug Announces Non-Brokered Offering of $650,000 of Convertible Secured Debentures and Issuances of Common Shares
Toronto, Ontario--(Newsfile Corp. - August 2, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $650,000 through the sale of debenture units ("Units"). Each unit is comprised of a $1,000 principal amount convertible...
2022-08-02 8:24 AM EDT
PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study
Toronto, Ontario--(Newsfile Corp. - June 16, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that the Company's enteric
2022-06-16 7:00 AM EDT
PharmaDrug Announces Execution Of an Agreement to Sell Its German Cannabis Asset to Khiron
Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into an agreement on May 31, 2022 with Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron") to sell all of the outstanding securities of Pharmadrug Production GmbH, ("Pharmadrug GMBH") the Company's wholly-owned German subsidiary, a medical cannabis distributor, with a Schedule I European Union narcotics license and German...
2022-05-31 8:46 AM EDT
PharmaDrug Announces Closing of the First Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - May 27, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the closing of the first tranche (the "First Tranche") of a non-brokered private placement (the "Offering") of units in the capital of...
2022-05-27 4:15 PM EDT
Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for Glaucoma
Toronto, Ontario--(Newsfile Corp. - May 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company
2022-05-03 8:00 AM EDT
PharmaDrug Advances Oncology Program with Filing of Provisional Patent Following Positive Findings for the Combination of PD-001 and Frontline Chemotherapy in Prostate Cancer Study
Toronto, Ontario--(Newsfile Corp. - April 19, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("
2022-04-19 7:30 AM EDT
PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure
Toronto, Ontario--(Newsfile Corp. - April 7, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such
2022-04-07 7:30 AM EDT
Pharmadrug Advances PD-001, Its Patented, Improved Version of Cepharanthine for Oncology and Infectious Disease
Toronto, Ontario--(Newsfile Corp. - April 1, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharma
2022-04-01 8:23 AM EDT
PharmaDrug Announces Interim Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Prostate Cancer Study
Toronto, Ontario--(Newsfile Corp. - March 9, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmace
2022-03-09 7:30 AM EST
PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma
Toronto, Ontario--(Newsfile Corp. - February 23, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-
2022-02-23 7:30 AM EST
PharmaDrug Announces Filing of US Provisional Patent for Cepharanthine to Treat Prostate Cancer
Toronto, Ontario--(Newsfile Corp. - February 1, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has filed a US provisional pa
2022-02-01 7:30 AM EST
PharmaDrug Announces Initiation of Manufacturing of Cepharanthine (PD-001) For Clinical Programs in Rare Cancers And COVID-19
Toronto, Ontario--(Newsfile Corp. - January 26, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has initiated the manufacturing of PD-001, a patented enteric-coated oral formulation of cepharanthine, for...
2022-01-26 8:28 AM EST
PharmaDrug to Present at Wall Street Reporter's "Next Super Stock" Livestream Conference on Tuesday January 25, 2022
Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company's Chairman and CEO Daniel Cohen will be presenting at Wall Street Reporter's "Next Super Stock" livestream...
2022-01-24 10:29 AM EST